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Human melanoma arises from epidermal melano-
cytes and displays remarkable phenotypic heteroge-
neity. This heterogeneity in part reflects the ability of 
melanoma cells to undergo differentiation along a 
pathway parallel to differentiation of normal mela-
nocytes. Tyrosinase, encoded by the albitlo (c), and the 
tyrosinase-related protein-1 or gp75, encoded by the 
browtl (b) locus, are two of the best-characterized 
markers for melanocyte differentiation. Both mole-
cules are glycoproteins expressed in melanosomes, 
the site of pigment synthesis. We studied the regula-
tion of these proteins in human melanoma cells 
induced by the polar-planar compound hexamethyl-
ene bisacetamide (HMBA). In well-differentiated 
melanoma cell lines, HMBA induced dendritic mor-
phology and specifically regulated the expression of 
melanosomal glycoproteins (but not a panel of other 
molecules expressed by melanoma cells). HMBA spe-
cifically down-regulated gp75 expression by rapidly 
decreasing the steady-state level of gp75 mRNA and 
M elanocytes are derived by differentia tion of pre-cursor melanoblast.s that originate and migrate from neural crest [1]. Progressive differentiation of melanoblasts in the skin during embryonic and neonatal development produces pigmented, 
dendritic melanocytes of the adult epidermis. Three distinct stages 
in melanocyte differentiation-early, intermediate, and late-have 
b een proposed based on the expression of a set of cell surface and 
intracellular markers by cultured fetal, newborn, and adult human 
melanocytes and m elanoma cells [2] . The most striking character-
istic of mature melanocytes is the presence of the pigment me.lanin 
within specialized organelles, melanosomes . The appearance of a 
pigmented phenotype is accompanied by the expression of a set of 
melanosomal proteins and other m elanocyte-specific markers [3] . 
The albiu.o (c) .locus protein, tyrosinase, and the brow11 (b) locus 
protein, tyrosinase-related protein-1/gp75 , are two of the best-
characterized molecules expressed by mature human melanocytes 
[4-8). Both tyrosi11ase and gp75 are 75-kD integra] membrane 
glycoproteins localized to the melanosome [9,10). Tyrosinase is the 
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gp75 synthesis. HMBA was able to down-regulate 
gp75 expression even in the presence of cholera 
toxin, which when added alone induced a two- to 
threefold increase in gp75 expression. In contrast to 
uniform down-regulation of gp75 expression, HMBA 
could either up-regulate or down-regulate tyrosinase 
expression and pigmentation. Based on the differen-
tial regulation of gp75 and tyrosinase, melanoma 
cells could be classified into two groups. In one 
group, gp75 expression was coordinately regulated 
with tyrosinase activity and pigmentation. In the 
other group, gp75 expression and tyrosinase activity 
and pigmentation were dissociated (with pigmenta-
tion coupling to tyrosinase activity, not to gp75 
expression). These results show that in mature mela-
nocytic cells, regulation of gp75 expression follows a 
pattern that can be independent of regulation of 
tyrosinase and pigmentation. Key words: melatJosomal 
proteinslllexametlrylette IJisacetamidelcyclic AMP. J Ittvest 
Derma.tol 105:113-119, 1995 
critical enzyme required for melanin synth esis [6, 11]. T he bro11111 
locus in mice influen ces the type of melanin pigment (black versus 
brown) and pmduces diffe rent shades of coat colo r [1 2-14]. 
Studies with pharmacologic agents that induce phenotypic 
changes in m e lanom a cells i11 11itro have provided a basis for 
understanding m elanocyte and melanoma differentiation [3]. T hese 
studies have shown that human melanoma cell s have an ability to 
differentiate along a pathway that paraJl els normal melanocyte 
differentiation . Accordingly, three classes of melanoma cell lines 
can be ide ntified corresponding to the early, intermediate, and 
m ature melanocytes [2] . T hese studies have also shown that 
differentiation is accompanied by coordinated and sequential 
changes in phenotypic traits. When individual clones of early stage 
(gp75 and tyrosinase negative) m elan oma cells are induced to 
diffe rentiate by pho rbol ester, an activato r of protein kinase C 
(PKC), and/or by cholera toxin, which elevates cellular cyclic 
adenosine monophosphate (cAMP) levels, pigment synthesis and 
gp75 are up-regulated and cell s acqu ire dendritic morphology [2]. 
Very little is known about the regulation of tyrosinase and gp75 
in difl:erentiated melanocytes. For example, coincident with de-
creased growth of mature m e.lanoma cells, down-regulation of 
gp75 has been observed [2]. To understand the regulation of 
melanocyte differentiation products, we studied the effect of hexa-
m ethylene bisacetamide (HMBA) on the expression of gp75 and 
tyrosinase in pigm ented human m elanoma cells. HM.BA is a 
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polar-planar compound that has been shown to induce differenti-
ation of a number of murine and human tumor cells in 11itro [15-19] . 
In C loudman S91 murine melanoma cells, HMBA has been shown 
to inJtib it tyrosinase activ ity and melanogenesis induced by mela-
nocyte-stimulating hom10n e and isobutylmethylxanthine [1 8]. In 
tlus report, we sh ow that HMBA specifically down-regulates gp75 
in human melanoma cells and that regulation of gp75 expression 
can b e independent of tyrosinase and pigme ntation. 
MATERJALS AND METHODS 
Cell Culture Human melanoma ce ll s SK-MEL-19, SK-MEL-23 (clone 
22), and all other melanoma cells used were maintained as described earlier 
(8]. For experiments to stud y the effect of H M.BA on growth, 2 X 1 04 
cells/well were plated in 24-well plates (Costar) in 1 ml of growth medium. 
After allowing the cells to attach for 24 h. we replaced the medium with 
fres h growth medium (control) or medium containing 1, 3, or 5 mM 
HMBA. Cell s were fed every second day with medium (including HMBA). 
Cell growth was monitored by counting viable ce ll s using the trypan blue 
exclusion method. Ce lls fi·om six wells for each treatment on days 1 , 3, 5. 
and 6 were detached using 0.5 ml trypsin/ethylenediaminctetraacetic acid 
and counted using a hcnlocytonl ctcr. 
Antibodies Melanocyte glycoprotein antigens transferrin receptor, hu-
nlan le ukocyte antigen class I protein, rnclanotransfcrrin, n1 c lanon1a pro-
teoglycan, CALLA (gp100), gpl BO, gp45 , gp140/30, gp130 / 100/27124, 
gp11 0, gp140 (integrins) , gp130, gp57, melanosomal membrane glycopro-
tein (CF21 ), lysosomal membrane protein (LAMP-1 ), and antibodies to 
these proteins have been described earlier [3,9,20-25]. Mouse monoclonal 
antibody (MoAb) TA99 has been described earlier (3]. Polyclonal antibodies 
to denatured human gp75 were made in rabbits at Cocalico Biologicals Inc. 
(Reamstown, PA); gp75 was purified from human melanoma cell line 
SK-MEL-19, as described earlier (1 0). Two New Zealand White rabbits 
were injected with 25 p..g heat-denatured gp75 in complete Freund's 
adjuvant. Two weeks la ter, 15 p..g gp75 was injected with incomplete 
Freund's adju vant, followed by two more injections at intervals of3 weeks. 
During the immunizations, the rabbits were test bled to monitor anti-gp75 
response in the sera, and 2 weeks after the last injection, 30 ml of serum was 
co llected and stored in aliquots at - 20°C. 
Serologic Assays For enzyme-linked immunosorbcnt assay (ELISA) to 
measure the expression of mehinosomal antigens gp75 and CF21, 4 X 104 
cells were plated in Rat-bottom 96-well microliter plates (Costar). Mter 
allowing 16-24 h fo r complete attaclunent, we added HMBA to a final 
concentration ofl, 3, or 5 mM, and mecliwn was replaced every second day. 
Each day for up to 5 d, cell s in a se t of plates were washed with 
phosphate-buffered saline (PBS), fixed with methnnol:acetone (1:1) at 
- 20°C for .I 0 min, washed several times with PBS, and blocked with 5% 
gamma-globutin-free bovine serum in PBS for 0.5-1.0 h. T he plates were 
either used immedia te ly for immunoassay or stored at 4 °C until furthe r usc. 
In triplicate wells. 50 p..l of MoAb TA99 or CF21 serially diluted in 
gamma-globulin-fi·ee bovine serum in PBS was added and incubated at 
room temperature for 1-2 h. ELISA was performed as described earli er (1 0]. 
Wells that did not receive any antibody were used as reagent blanks, and 
severa l wells on each plate that received only alkaline-phosphatase- conju-
gated second antibody and the substrate were used to measure nonspecific 
antibody binding and endogenous alkaline phosphatase activity. 
Mixed Hemadsorption Assay Expression of ce ll surface antigens was 
assayed by d1e mixed hemadsorption assay. Briefly, 200-500 cells in 10 p..l 
were plated in microtiter plates (R.obins Scientifi c). Mter cell attachment for 
16-24 h, 5 p..l of appropriate stock solution of HMBA in growth medium 
was added to obta in a final concentration of 1, 3, or 5 mM HMBA. Cells 
were grown at 3 7°C. Every second day, spent medium was aspirated using 
a syringe and needle and rep laced with 1 0 p..l fresh medium with an· 
appropriate final concentration of HMBA . On days 1, 3 , and 5, the plates 
were washed once with PBS, and mixed hemadsorption assays with various 
antibodies were performed as described ea rlier f2]. 
Irnrnunoprecipitation Metabolic (continuous and pulse/chase) labeling 
of cell s in cul ture with 35S-methlonine, cel l lysis, and immunoprecipitation 
with MoAb TA99 were performed as described ea rl.i er [8). Rabbit anti-
mouse tyrosin<lse antibody (a generous gift from Dr. Bryan Fuller, Univer-
sity of Oklahoma Medical School) fo llowed by protein A Sepharosc was 
used to precipitate metabolically labeled tyrosinase . lmmunoprecipitates 
were analyzed by sodium dodecylsul£1tc-polyacrylamide gel electrophoresis 
(SDS-PAGE) and visualized by Auo rography, and immunoprecipitated 
proteins were quantitated by counting radioactivity in the regions of dried 
gels corresponding to the bands on d1e film. 
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Western Blot Analysis Cell pellets were washed thoroughly and lysed 
in lysis buffer containing 1% Nonidet P-40, 0.5% deoxycholate, and 
protease inhibitors leupeptin , pepstatin, aprotinin, and phenylmethylsulfo-
nyl fluoride. Detergent-soluble protein was estimated using the BioRad De 
Protein Assay system (BioRad, Richmond, CA). Twenty-five micrograms 
of protein from each lysate was electrophoresed on 9% polyacrylam.ide gels 
and transferred to lmmobilon (M.illiporc, Marlborough, MA), as described 
ea rli er [1 0]. T he blots were then incubated for 1 h with rabbit anti-human 
gp75 serum diluted 1:1000, followed by incubation with peroxidase-
conjugated goat anti-rabbit IgG diluted 1 :20,000. llound peroxidase-
conjugated anti-rabbit IgG was visualized by chemiluminescence using the 
ECL detection kit {Amersham, Arlington Heights, IL). 
Northern Analysis Tota l cytoplasmic RNA was isolated from cells in 
semiconAuent 150-cm2 Aasks as described earlier [6]. Approximately 25 p..g 
ofRNA was electrophoresed in 1% agarose gels con taining fom1aldehyde, 
blotted onto GeneScreen membrane (NEN Dupont) by capillary transfer, 
prehybridized according to the manuf:1cturer's instructions, and hybridized 
with 3 2P-Iabcled full-length eDNA probes for human gp75 and tyros inase at 
42°C (6,7]. T he blots were washed with 2 X sodium citrate/sodium 
chloride buffer at room temperature for 5 min, then with 2 X sodium 
citrate/sodium chloride containing l '!lo SDS at 60°C for 30 min , and finally 
with 0.1 X sodium citrate/sodium chlo ride at room temperature for 30 min. 
The blots were exposed to fum for autoradiography with one intensifying 
screen . 
Tyrosinase Assays Tyrosine hydroxylase actlvlty in cell lysates was 
measured as described earli er (10]. llrieAy, enzyme activity in 1% Triton 
X-1 00 lysates equivalent to 1 06 cell s was assayed in triplicate in a final 
reaction volume of200 p..l containing 0.2-0.3 p..Ci 3 H-tyrosine at 37°C for 
1 h. After adsorption of the reaction mixtures to activated charcoa l, counts 
released as 3H 20 were measured in a liquid scintillation counter. Back-
ground counts obtained as 3I-J 2 0 released in buffer control tubes without 
cell extracts were equal to or less than 10% of counts obtained in tubes wid1 
cell extracts. Background counts were subtracted from counts obtained for 
each reaction tube, and the mean ::':: SD of triplicate values is shown. 
RESULTS 
HMBA Induces Dendritic Extension and Multidendritic 
Morphology in Melanoma Cells Human melanoma cell lines 
SK-MEL-19 and SK-MEL-23 clone 22 (clone 22) express phe no-
typic traits c haracteristic of the m ature stage of melanocytic di1fer-
entiation [2]. SK-MEL-19 cells are spindle-shape d with short 
dendrites and have dark broW11 to black pigmentation, and clone 22 
cells display spindle-shaped bipolar morphology with black pig-
mentation. Both SK-MEL-19 and clone 22 cells culture d in the 
presen ce of HMBA acquired a polydendritic morphology. In the 
presen ce of 1 or 3 mM HMBA, there was no d e tectable c hange in 
the growth of tl1e two m e lanoma cell lines. In 5 mM HMBA, both 
cell lines exhibited a m easurable decrease in growth rates. At the 
e nd of four population doublings, the m e an doubling time for 
SK-MEL-19 cells increased from 29 h in control conditions to 49 h 
in 5 mM HMBA. For clone 22, the m ean doubling time increased 
from 23 b to 47 h in 5 mM HMBA (data not shown). No further 
decrease in the growth rate was apparent over long p e riods of 
incubation, even when 5 mM HMBA was present in the c ulture 
m e dium continuously for 3 weeks (mean population doubling time 
for both cell lines increased from 26 h to 57 h, i.e. , a twofold 
increase) . 
Down-Regulation of gp75 (the b Locus Protein) in Mela-
noma Cells: A Specific Response to HMBA W e studied the 
effect of HMBA on the expression of gp75 by ELISA and by 
immunofluorescence staining u sing MoAb TA99. In both SK-
M EL-19 and clone 22 m e lanoma cells c ultured in the presence of 
HMBA, there was a d ecrease in g p75 expression. The e ffect was less 
pronounce d in SK-MEL-19 cells and showed no clear relation to 
the con centration of HMBA. In clone 22, the d ecrease in expres-
sion of gp75 was depe ndent on the con centration of H .MBA. After 
5 d in the presence of 5 mM HMBA, gp75 expression in clone 22 
cell s was almost comple te ly extingui shed (Figs 1, 2) . In all seven 
m elanoma cell lines tested, including the mouse melanoma Bl6, 
treatment with HMBA resulte d in a 40% to 90% decrease in gp75 
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Figure 1. Effect ofHMBA on gp75 expression. SK-MEL-1 9 (lift) ;md 
clone 22 (right) melanoma cells grown in 96-well plates were ftxed and 
pem1eabilizcd, and gp75 was measured by ELISA using MoAb TA99. Data 
arc represented as antibody titration curves for untreated control cells (opc11 
tria11gles) and cells treated with HMBA {5 mM for 5 d) (closed lriflllgles). Each 
data point represents values obtained from four wells. Emn· bars represent ± 
SD . 
synthesis (see below and Table 1). We chose SK-MEL-19 and 
clone 22 cell lines for detailed analyses . 
HMBA did not induce any detectable change in the expression of 
16 other glycoproteins expressed by melanocytes and melanoma 
cell ljnes SK-MEL-19 and clone 22. These included cell surface 
proteins (transferrin receptor, integrins, melanoma proteoglycan, 
and a melanocyte-specific cell surface antigen) and intracellular 
membrane proteins (melanosomal CF21 and lysosomal membrane 
glycoprotein, LAMP-l) (data not shown) . There was no decrease in 
total cellular protein synthesis or glycoprotein synthesis induced by 
HMBA (as measured, respectively, by incorporation of 355-meth.i-
on.ine and 3 H-glucosamine by clone 22 cells into newly synthesized 
proteins). These data showed that HMBA specifically regulated 
expression of gp75, a protein that is intimately associated with 
pigmentation, a differentiated phenotype of melanocytic cells. 
HMBA-Induced Down-Regulation of gp75 Expression Oc-
curs at the Single Cell Level and Is Reversible The decrease 
in synthesis and expression of gp75 measured in bulk cultures could 
be a result of either down-regu lation of gp75 synthesis by HMBA 
at the individual cell level or selective expansion of a subpopulation 
of cells that express little or no gp75. To examine these possibilities, 
we studied gp75 expression in clone 22 cells by immunofluores-
cence mjcroscopy using MoAb TA99. As shown in Fig 2, detect-
able but varying levels of gp75 expression could be seen in almost 
all cells of clone 22. In the presence of 3 rnM HMBA for 5 d, only 
a very smal.l population of cells showed weak to moderate staining 
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Table I. Differential Regulation of gp75 and Tyrosinase 
in Melanoma Cells by HMBA" 
% C hange 
gp75 Tyrosinase 
Cell Line Synthesis Activity 
SK-ME L-1 9 - 85 + 14 
SK-MEL-2 1 - 88 + 56 
SK-MEL-30 - 75 + 33 
SK-MEL-188 - 56 + 35 
Bl6 (mouse) - 60 + 69 
SK-MEL-93 (2) - 39 - 58 
SK-MEL-23 
(clone 22) -88 - 40 
" T yrosinase acti\dty and gp75 syntl1csh were measured in various melanoma cell 
lines grown i.n the presence of 5 mM HMBA for 5 d. Tyrosine hydrolyase activity was 
measured as release of 3 1-1 2 0 . and gp75 synthesis was estimated by metabolic labeling 
with 3 5S-mcthioninc, as described in the legend fo r Figs 4 and 5. Data arc shown as 
percent enzyme activi ty or synthesis comp.1 red with the un treated concrol of each cell 
line . 
for gp75 expression . In 5 mM HMBA for 5 d , there was almost no 
detectable gp75 staining. Tl:lls pattern of loss of gp75 e"-1'ression, 
related to time and HMBA concentration, showed that HMBA 
down-regulated gp75 eJo.:pression at the individual cell level. In 
support of this noti.on, HMBA-induced down-regulation of gp75 
was reversible . Within 24 h of removal of HMBA, a moderate to 
intense re-expression of gp75 could be seen in gp75-negative cells 
(Fig 3) . This rapid reappearance o f gp75 expression occurred 
uniformly in the entire population within a short period (1 2-24 h) 
with no detectable increase in cell number. These results showed 
that down-regulation of gp75 synthesis by HMBA occurred at the 
individual cell level and not simply by selective expansion of a 
subpopulation of gp75-negative cells. 
Pigmentation and Tyrosinase Activity: Heterogeneity in 
Response to HMBA Clone 22 and SK-MEL-19 cells showed a 
distinct response to HMBA with respect to melanin pigmentation . 
After 5-7 d of treatment with HMBA, clone 22 cells became lightly 
pigmented, with occasional completely depigmented cells . On the 
otl1er hand, HMBA induced an increase in pigmentation in SK-
MEL-19 cells compared with untreated cells . Examination of pellets 
of clone 22 and SK-MEL-1 9 cells treated witil HMBA showed, 
respectively, lighter and darker pigmentation (data not shown). 
Tyrosinase, wlllch catalyzes the initial steps of tyrosine hydroxyla-
tion and oxidation of dihydroJo..}'phenyla.lanine, is the critical and 
rate-limiting enzyme required for melanin synthesis. To investigate 
whether the observed differences in pigmentation w ere due to an 
effect of HMBA on tyrosinase activi ty, we measured tyrosine 
hydroxylase activity of tyrosinase in lysates of SK-MEL-19 and 
Figure 2. HMBA down-regulates 
gp75 expression in differentiated 
melanoma cells. C lone 22 melanoma 
cells were grown on tnlllti- wc!J cham-
ber glass slides without (A) o r with 1 
mM (B) , 3 mM (C,D) , or 5 mM HMBA 
(E,F) for 5 d . Cells were fi xed, p cnue-
abilizcd, and stained fo r gp75 expres-
sion and photographed . C,E, phase 
contrast micrographs o f fields corre-
sponding to areas in D and F. Bar, 250 
J.J.lll. 
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Figure. 3. Down-regulation of gp75 by HMBA occurs in individnal 
cells and is reversible. Clone 22 melanoma cells were grown in duplicate 
wells of glass chamber slides without (A) or with 1 mM (B,C) , 3 mM (D,E) , 
or 5 mM (F,G) J-IMJ3A for 5 d. O n day 5, one slide was fixed, and medium 
in wells on the other slide was replaced with HMB A-frce medium, 
incubated for an additiona l 24 h, and then fixed (C,E,G) . Permeabilized 
cells were stained for gp75 expression with MoAb TA99. Bar, 250 fLm . 
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Fig ure 4. Tyrosinase activity in melanoma cells shows variable 
response to HMBA. Tyrosine hydro>-)' lase activity was measured as 
release of 3 1-1 2 0 from 3 1-1-tyrosinc using lysates of SK-M.EL-19 (/tift) and 
clone 22 (right) melanoma cells grown in the presence of 1 mM (circles), 3 
mM (apeu lrilluglcs). or 5 mM (clo set{ lrin ug lcs) HM13A up to 5 d. T he data 
shown arc representative of three independent experiments. In control 
untreated cell s, the enzyme activity me:osurcd as counts in 3 1-1 20 ranged 
from 200 .000 to 400,000 cpm/mg protein/h. Enzyme activity in cclllysates 
at different times is shown as percent activity of control cells brrown without 
HMBA. 
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Figure 5. D e uovo gp75 biosynthesis is inhibited by HMBA. A, 
SK-MEL-19 and done 22 cells grown in 1, 3, and 5 mM J-IMBA were 
metabolica lly labeled Mth 35S-methionine for 90 min on day 5. Newly 
synthesized gp75 was immunoprecipitated using MoAb TA99 and analyzed 
by SDS-PAGE. B, tyrosinase was immunoprecipitated from SK-MEL-19 
and clone 22 cells using a rabbit anti-mouse tyros inase antibody after 4 h of 
metabolic labeling. C, lysate from contwl cells grown without J-IMBA; H, 
lysates from cells grown in 5 mM HMBA for 5 d . 
clone 22 cells treated with 1, 3, and 5 mM HMBA (Fig 4). In 
SK-MEL-19 cells, all three concentration s of HMBA caused a 
modest but reproducible increase (up to 30% compared with 
untreated cells) in tyrosinase activity . In contrast, in clone 22 cells, 
a 50% decrease in tyrosinase ac tivity was observed as early as 24 h 
in 1 mM HMBA. No further decrease in the en zyme activ ity could 
be seen at hig her con centrations of HMBA (up to 5 mM) o r by 
extending the time of exposure to HMBA up to 5 d (Fig 4) . T hese 
effects of HMBA on tyrosinase activity in melanoma cells were 
reproducible in five independe nt experiments and were consistent 
with the o bserved effects ofHMBA o n pigmentation in individual 
experim ents, i.e ., a modest but reproducible increase in tyrosinase 
activity and darker m elanin pigmentation of SK- MEL-19 cells and 
a decrease in en zym e ac tivity and Hghter pigmentation of clone 22 
cells. 
HMBA Inhibits Steady-State Accumulation of gp75 mRNA 
and Biosynthesis of gp75 We studied the biosynthesis of gp75 
in untreated and HMBA-treated m elanom a cells to understand 
whether modulation of gp75 by HMBA was due to its effects on 
synthesis or stability of the protein. After 5 din 5 mM HMBA, very 
Httle or n o new gp75 synthesis could b e de tected in eithe r 
SK-MEL-19 or clone 22 cells (Fig SA) . Inhibition of gp75 synthesis 
appeared to be regul ated at the level of transcription or stability of 
gp75 mRNA. In the presen ce of5 mM HMBA, the amount ofgp75 
mRNA was markedly decreased in both melanoma cell lines (Fig 
6) . We quantitated the inhibition of gp75 biosynthesis by m easur-
ing the radioactivity in gp75 protein bands. In clone 22 cells 
cultured for 48 h in 1 mM HMBA, gp75 synthesis d ecreased to 30% 
of untreated con trol ceUs, whereas in SK-MEL-19 cells , comparable 
inhibition was observed only after treatment with 3 mM HMBA for 
5 d . Almost complete inhibition of gp75 synthesis could be seen in 
both cell lines cultured for 5 d in 5 tnM HMBA. These results 
together with the data in Table I show that, al though the degree of 
inhibition varied , HMBA down-regulated de llOVo synth esis of gp75 
in all seven melanoma cells lines tested. 
Although synthesis of gp75 was effectively inhibited by HMBA in 
both SK-MEL-19 and clone 22 cells, an am oun t of protein detect-
able by ELISA was present in SK-MEL-19 cells cultured i11 the 
presence ofHMBA. T l:t.i s was in contrast to a complete depletion of 
gp75 by HMBA in clone 22 cells (Fig 1). This did not appear to be 
due to differen ces in the effect of HMBA on stabili ty/half-life of 
newly synthesized gp75 between these cell lines . Pulse-chase 
m e taboHc labeling experim ents showed that HMBA did not cause 
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Figure 6. HMBA specifically decreases the steady-state gp75 
rnRNA in melanoma cells . Twenty-live micrograms of tota l cytoplasmic 
RNA iso lated fro m ce ll s gmwn in medium alone (0) or in I mM , 3 mM , o r 
5 mM HMBA fo r 5 d was e lectrophoresed o n denaturing aga rose gels. 
transferred to GeneScrecn , and probed, sequentially, w ith random prim e-
labeled full-l ength cON As for ryrosinasc (Tyr) and gp7 5. It sho uld be noted 
that the appare n t in crease in signal for tyrosinase in clone 22 ce ll s treated 
w ith 3 mM HMJlA is due to a sUgh tly larger amo unt of RNA loaded in the 
lane marked 3 mM HMBA o n the blot containing R.NA &om clone 22 cells 
(as shown by ethidium bro mide IEtB r] sta ining) . 
any measurable ch an ge in the swbility / hal f- life of newly synthe-
sized gp75 in either SK-MEL-1 9 o r clone 22 ce lls. O ne possible 
explana tion fo r the persistence of m easurable gp75 in SK-MEL-1 9 
cells co uld be accumul atio n and lo nger in tracellul ar retention of 
melanosomes in SK-MEL-19 ce lls compared with clone 22 cell s. 
Electron microscopic examin ation of the high-speed particula te 
fractio n of spent culture medium sho wed pigmented melanosomes 
u1 the cu ltu re medium o bta ined fi:om clone 22 cells, w he reas no 
pigmented me lan osomes could be seen in medium obtajned from 
SK-MEL- 19 cell s (data not shown). T h.is suggested that persistence 
of gp75 expression in H MBA-treated SK-MEL-19 cells is due to 
ine ffi cient re lease of gp75-containing pigmented m e lanosomcs into 
the medium by these cell s. 
HMBA Has No Effect on the Steady-State mRNA Levels of 
Tyrosinase T here was very little or no difference in the autora-
diograph.ic in tensity of prote in bands immunoprecjpitated by anti-
tyrosinase antibody fro m control SK-MEL-·19 cells or cells treated 
with 5 mM HMBA for 5 d. In clone 22 cells, treatment with 5 mM 
HMBA resul ted in a decrease in immunoprecipitable tyrosinase 
(Fig SB). However, this decrease in tyrosinase did not appear to be 
du e to a decrease in ty rosin ase mRNA. HMBA did not a/feet 
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steady-sta te tyros inase mRNA levels in either SK-MEL-19 or clone 
22 cells (Fig 6). 
T hese results suggested that HMBA regul ated de novo synthesis of 
tyrosinase in SK-MEL-19 and clone 22 cel.l s w ith no marked effect 
on the accumul ation of tyrosinase mRNA. 
Effect ofHMBA on gp75 and Tyrosinase Expression: Impli-
cations for Differences in Pathways of Regulation We 
compared the e ffects ofHMBA w ith those of other phannacologic 
agen ts known to induce phenotypic changes in human melanoma 
cells to understand the possible pathways o f regulation of gp75 by 
HMBA . We m easured gp75 expression and tyrosine hydroxylase 
activ ity in SK-MEL-19 and done 22 m e lanoma cells cultured in the 
presence of HMBA, 12-0-tetradeca.noyl-phorbol-13-acetate 
(TPA) , or cholera to:>..in alo ne; or in a combination of.HMBA and 
TPA or HMBA and cholera toxjn. 
In both SK-MEL-1 9 and clone 22 cell lines, cholera toxin added 
alone induced a two- to fo urfo ld increase in gp75 expression. TPA 
had no e ffect on gp75 expression . W hen added together witl1 
cho lera toxin or TPA, HMBA was still able to down-regulate gp75 
expression in both cell lines (Fig 7A). 
SK-MEL-1 9 and clone 22 cell s showed distinct responses in 
tyrosinase activjty to HMBA, and to HMBA in combination with 
cho lera to:>..i n . When added a l.one, HMBA induced a l.S-2-fold 
increase in SK-MEL-19 tyrosinase and caused a 50% decrease i.n 
clo ne 22 tyros inase activity. C ho lera toxj.n had no effect on 
HMBA-induced tyrosin ase activity in SK-MEL-19 cel.l s (Fig 7B) . 
In clone 22, down-regulation of tyrosinase by HMBA was effec-
tively blocked when cholera toxin was added to the medium 
toge ther w ith HM_BA. T hese resul ts showed that gp75 expression 
in both m elano m a cell Lines was regulated by pathways that can be 
inhibited by HMBA. T he inhibitory effect of HMBA on gp75 was 
dominant over cAMP-jnduced up-regul.a6on of gp75 expressio n. 
T hese results also suggested that in m ature m elanom a ceU lin es, 
gp75 expression was regulated by similar pathways, w hereas tyros i-
nase expression was regulated by at leas t two d.istinct pathways . 
D ISCUSSION 
Compara6ve studies of the express ion of ce l.l surface and intracel-
lular markers by human m elanomas and their nonnal progenitor, 
epidermal m elanocyte . have allowed identification of three classes 
of m elanom a cells that correspond to differen t stages in m elanocyte 
differentiation [2] . The ability of melanoma cells to differentiate is 
apparent both i11 11i1JO and i11 JJitro. First, the presence of popula6ons 
of me lanom a cells at different stages of difl:e rentiation withjn a 
single m etasta tic lesio n recapitulates the remarkable phenotypjc 
heterogeneity seen i11 JJi/ ro [2]. Second , upon induction with 
activators of PKC and adenyl cyclase, m elanoma cells i11 JJitro 
undergo differen tiation. For instance, nonpigmented melanoma 
cells that are induced to diffe rentiate manifest increased melanjn 
synthesis and coordin ated up-regula tion of a fatnily of proteins , 
including m elanosomaJ glycoprotcins [3] . T hus, regulation of pro-
tein s associated with m e lanin synth esis is an integral part of 
mclanocytic differen tiation . Tyrosinase and gp75, w hich are asso-
ciated w ith melanin synthesis, are two of tl1e best-characterized 
m elanosomal proteins [4 -8]. Our data show that HMBA specifi-
cally down-regulates the expression of gp75 in melanoma cells and 
that in m ature m e lanocytic cells, gp75 can be regulated indepen-
dently of pigmentation , tyrosinase, or othe•· specific differentiation 
traits . 
In some melanom a cells. regulation of gp75 and tyrosin ase 
appears to be 6 ghtl y coupled , and jndu cers that modulate the 
expression of gp75 also modulate the expression ~md activity of 
tyrosinase (Table 1). T lus closely linked control of che two 
di.lferentiatio n gene products is presumed to reflect the coordinated 
regulation of tyrosinase and gp75 dm-ing norma l melanocytic 
differentiatio n . In a subset of m elanomas represen ted by SK-MEL-
19, the regulation of these proteins is u_ncoupled , i.e., down-
regulation of gp75 and up-regulation of ty1·osinase by the sam e 
pharmacologic agent (Table 1). T he absence of a coordinated 
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Figure 7. Down-regulation of gp7S by HMBA is dominant over 
cholera-toxin-induced up-regulation of gp7S expression. A, West-
ern blot analysis of gp75 expression. One hundred micrograms of detergent-
so luble cellular proteins from cells grown for 5 d in medium alone (C) , 
cholera toxin (CT) alone, or HM.BA (H) alone, and in a combination of 
cholera toxin and HMDA (CT+H), was electrophoresed on 9% SDS-
PA GE, transferred to Immobilon , and probed with rabbit anti-gp75 anti-
body, and protein bands were detected by chemiluminescence. B, Tyrosine 
hydroxylase activity in SK-MEL-19 (top) and clone 22 cells (bot/om) was 
measured in lysates obtained from cells grown for 5 d in medium alone (C), 
with cholera toxin (CT), HMDA (H) , or in a combination of cholera toxin 
and HMDA (CT+ H) . Data from triplicate assay tubes corrected for 
background counts with buffer control are shown. Error bnrs represent :t 
SD. The experiment was repeated three times and in each experiment, 
tripbcate sample mean va lues for enzyme activity in cells trea ted with 
1-JMBA, cholera toxin , or 1-JMDA plus cholera toxin were significantly 
different relative to control (Student t test; p S 0.05). 
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regulation of these two gene products may represent an altemative 
pathway with in late-stage m elanocyte differentiation . Alternatively, 
these differen ces could be a res ult of events occurring during tumor 
progression and, therefore, unre lated to the m elanocyte diffe renti-
ation program. Given that tyrosinase and gp75 ca n be regulated 
independently b y HMBA in m ost melanoma cell lines tested, we 
favor the former possibility. 
The effec ts of HMBA on a numbe r of murine and human tumor 
cells in 11itro have been investigated. Induction of termina l differ-
entiation of murine erythro le ukemia cells is by f.'lr the most 
extensively studied eB:ect of HMBA of cancer cells. In this model, 
HMBA has been shown to modulate specif ically the expression of 
gen es regu lating cell proliferation , as we!J as genes associated with 
the terminall y differentiated ph enotype of e rythroid cells (e .g., 
globin genes) (26,27]. Our data show that HMBA specifica.lly 
modulates the expression of tyrosinase and gp75 in mature mela-
n oma cells . W e noted that down- regulation of gp75 and tyrosinase 
by HMBA was not accompanied by the re-expression of proteins 
that define ea rly stages of m elanocyte diffe rentiation. Although 
HMBA up-reguJated tyrosinase in SK- M.EL-19 cells, HMBA did 
not induce tyrosinase or alte r the expression of early m e lanocyte 
differentiation markers in nonpigm ented, early melanomas (Vija-
yasaradhi et al, unpublish ed observations). Thus, specific down-
regulation of gp75 and differential regulation of tyros inase by 
HMBA in m ature m elanomas shows that these traits can be 
regulated within the mature stage of melanocytic differentiation and 
do not represent a reversal to a less differentiated phenotype . 
PKC has been shown to be involved in the pathway ofHMBA-
induced diffe rentiation in murine erythroleukemia cells [28,29]. 
Agents that deplete PKC or prevent the conversion of the m em-
brane-bound form to the soluble fonn of PKC block HMBA-
i.nduced differentiation of murine erythroleukemia cells [26]. In 
SK-M.EL-19 m elanoma cells, the effects of HMBA on tyrosinase 
were blocked by TPA, consistent with a possible involvement of 
the PKC-mediated pathway for tyrosinase regu.lation (data not 
shown). However, in done 22 cells, cholera tox in (which ca uses 
e levation in i.ntrace!Jular cAMP levels) , but not T PA, blocked the 
inhibitory effect of HMBA on tyrosinase expression. These obser-
vations are consistent with the effects of cAMP agonists, such as 
melanocyte-stimulating hormone, on tyrosinase activity in mouse 
melanoma cells and support the notion that tyrosinase is regulated 
by multiple pathways (4,30,31 ]. It is inte res ting that HMBA not 
only blocked chol e ra toxin-induced stimulation of gp75, but was 
able to extin guish compl etely gp75 expression even in the presence 
of cholera toxin . Thus, HMBA inhibition of gp75 expression is 
dominant over cAMP-mediated pathways that up-regulate gp75 
expression . These results highlight the differen ces in the regulation 
of tyrosinase and gp75. 
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